136 related articles for article (PubMed ID: 30057295)
1. Efficacy and safety of glucocorticoids in rheumatoid arthritis: Systematic literature review.
Sanmartí R; Tornero J; Narváez J; Muñoz A; Garmendia E; Ortiz AM; Abad MA; Moya P; Mateo ML; Reina D; Salvatierra-Ossorio J; Rodriguez S; Palmou-Fontana N; Ruibal-Escribano A; Calvo-Alén J
Reumatol Clin (Engl Ed); 2020; 16(3):222-228. PubMed ID: 30057295
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Combined Therapy With Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis: Systematic Literature Review.
Calvo Alén J; Pérez T; Romero Yuste S; Ferraz-Amaro I; Alegre Sancho JJ; Pinto Tasende JA; Maceiras Pan F; Quevedo JC; Hernández-Hernández MV; Hidalgo Calleja C; San Martín Álvarez A; Sánchez MIT; Sanmartí R
Reumatol Clin (Engl Ed); 2020; 16(5 Pt 1):324-332. PubMed ID: 30241955
[TBL] [Abstract][Full Text] [Related]
3. Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis.
Gorter SL; Bijlsma JW; Cutolo M; Gomez-Reino J; Kouloumas M; Smolen JS; Landewé R
Ann Rheum Dis; 2010 Jun; 69(6):1010-4. PubMed ID: 20448288
[TBL] [Abstract][Full Text] [Related]
4. Experts document on methotrexate use in combined therapy with biological or targeted synthetic disease modifying drugs in patients with rheumatoid arthritis.
Tornero-Molina J; Alperi-López M; Castellví I; de Agustín-de Oro JJ; Escudero A; García-Vicuña R; González-Gay MÁ; Hidalgo C; Rubio E; Sanmartí R; Casamira N; Calvo-Alén J
Reumatol Clin (Engl Ed); 2022 Jan; 18(1):33-41. PubMed ID: 35090610
[TBL] [Abstract][Full Text] [Related]
5. Ability of disease-modifying antirheumatic drugs to prevent or delay rheumatoid arthritis onset: a systematic literature review and meta-analysis.
Hilliquin S; Hugues B; Mitrovic S; Gossec L; Fautrel B
Ann Rheum Dis; 2018 Aug; 77(8):1099-1106. PubMed ID: 29884751
[TBL] [Abstract][Full Text] [Related]
6. Expert Recommendations on the Interleukin 6 Blockade in Patients with Rheumatoid Arthritis.
Tornero Molina J; Balsa Criado A; Blanco García F; Blanco Alonso R; Bustabad S; Calvo Alen J; Corominas H; Fernández Nebro A; Román Ivorra JA; Sanmartí R
Reumatol Clin (Engl Ed); 2020; 16(4):272-281. PubMed ID: 30098882
[TBL] [Abstract][Full Text] [Related]
7. Efficacy, duration of use and safety of glucocorticoids: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis.
Bergstra SA; Sepriano A; Kerschbaumer A; van der Heijde D; Caporali R; Edwards CJ; Verschueren P; de Souza S; Pope JE; Takeuchi T; Hyrich KL; Winthrop KL; Aletaha D; Stamm TA; Schoones JW; Smolen JS; Landewé RBM
Ann Rheum Dis; 2023 Jan; 82(1):81-94. PubMed ID: 36410794
[TBL] [Abstract][Full Text] [Related]
8. "Official View" on Glucocorticoids in Rheumatoid Arthritis: A Systematic Review of International Guidelines and Consensus Statements.
Palmowski Y; Buttgereit T; Dejaco C; Bijlsma JW; Matteson EL; Voshaar M; Boers M; Buttgereit F
Arthritis Care Res (Hoboken); 2017 Aug; 69(8):1134-1141. PubMed ID: 28029750
[TBL] [Abstract][Full Text] [Related]
9. Glucocorticoids in rheumatoid arthritis: current status and future studies.
Hua C; Buttgereit F; Combe B
RMD Open; 2020 Jan; 6(1):. PubMed ID: 31958273
[TBL] [Abstract][Full Text] [Related]
10. Indications of glucocorticoids in early arthritis and rheumatoid arthritis: recommendations for clinical practice based on data from the literature and expert opinion.
Mouterde G; Dernis E; Ruyssen-Witrand A; Claudepierre P; Schaeverbeke T; Cantagrel A; Gaudin P; Maillefert JF; Pham T; Saraux A; Tebib J; Wendling D; Fautrel B; Le Loët X
Joint Bone Spine; 2010 Dec; 77(6):597-603. PubMed ID: 20594896
[TBL] [Abstract][Full Text] [Related]
11. Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis.
Gaujoux-Viala C; Smolen JS; Landewé R; Dougados M; Kvien TK; Mola EM; Scholte-Voshaar M; van Riel P; Gossec L
Ann Rheum Dis; 2010 Jun; 69(6):1004-9. PubMed ID: 20447954
[TBL] [Abstract][Full Text] [Related]
12. When and for how long should glucocorticoids be used in rheumatoid arthritis? International guidelines and recommendations.
Gaujoux-Viala C; Gossec L
Ann N Y Acad Sci; 2014 May; 1318():32-40. PubMed ID: 24827544
[TBL] [Abstract][Full Text] [Related]
13. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
van Herwaarden N; den Broeder AA; Jacobs W; van der Maas A; Bijlsma JW; van Vollenhoven RF; van den Bemt BJ
Cochrane Database Syst Rev; 2014 Sep; (9):CD010455. PubMed ID: 25264908
[TBL] [Abstract][Full Text] [Related]
14. Incident diabetes associated with hydroxychloroquine, methotrexate, biologics and glucocorticoids in rheumatoid arthritis: A systematic review and meta-analysis.
Xie W; Yang X; Ji L; Zhang Z
Semin Arthritis Rheum; 2020 Aug; 50(4):598-607. PubMed ID: 32480098
[TBL] [Abstract][Full Text] [Related]
15. Experts document on methotrexate use in combined therapy with biological or targeted synthetic disease modifying drugs in patients with rheumatoid arthritis.
Tornero-Molina J; Alperi-López M; Castellví I; de Agustín-de Oro JJ; Escudero A; García-Vicuña R; González-Gay MÁ; Hidalgo C; Rubio E; Sanmartí R; Casamira N; Calvo-Alén J
Reumatol Clin (Engl Ed); 2020 Oct; ():. PubMed ID: 33041228
[TBL] [Abstract][Full Text] [Related]
16. Penicillamine for treating rheumatoid arthritis.
Suarez-Almazor ME; Spooner C; Belseck E
Cochrane Database Syst Rev; 2000; (4):CD001460. PubMed ID: 11034719
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of glucocorticoids, conventional and targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis.
Chatzidionysiou K; Emamikia S; Nam J; Ramiro S; Smolen J; van der Heijde D; Dougados M; Bijlsma J; Burmester G; Scholte M; van Vollenhoven R; Landewé R
Ann Rheum Dis; 2017 Jun; 76(6):1102-1107. PubMed ID: 28356243
[TBL] [Abstract][Full Text] [Related]
18. An updated review of glucocorticoid-related adverse events in patients with rheumatoid arthritis.
Luís M; Freitas J; Costa F; Buttgereit F; Boers M; Jap DS; Santiago T
Expert Opin Drug Saf; 2019 Jul; 18(7):581-590. PubMed ID: 31056959
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of TOcilizumab in comparison to Prednisone In Rheumatoid Arthritis patients with insufficient response to disease-modifying antirheumatic drugs (TOPIRA): study protocol for a pragmatic trial.
van der Leeuw MS; Welsing PMJ; de Hair MJH; Jacobs JWG; Marijnissen ACA; Linn-Rasker SP; Fodili F; Bos R; Tekstra J; van Laar JM
Trials; 2020 Apr; 21(1):313. PubMed ID: 32248829
[TBL] [Abstract][Full Text] [Related]
20. Canadian Rheumatology Association recommendations for the pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs: part II safety.
Bombardier C; Hazlewood GS; Akhavan P; Schieir O; Dooley A; Haraoui B; Khraishi M; Leclercq SA; Légaré J; Mosher DP; Pencharz J; Pope JE; Thomson J; Thorne C; Zummer M; Gardam MA; Askling J; Bykerk V;
J Rheumatol; 2012 Aug; 39(8):1583-602. PubMed ID: 22707613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
